LBI-0222

THERAPEUTIC AREA

BRAIN CANCER

LBI-0222

Indications:
Multiple Myeloma, Leukemia
REGULATORY PATHWAY

New NDA

TARGET INDICATION

New chemical entity (NCE) kinase inhibitor analogue

CURRENT DEVELOPMENT STATUS

Molecules have been designed. Development is paused until funding and staff are secured and solid tumor program advances to human trials

NEXT DEVELOPMENT PHASE

Utilize Luminus nano-platform to synthesize multiple drug molecules and rational drug combinations, screen and select lead candidate

TIME TO HUMAN BENEFIT

Human trials beginning as soon as 2 years from funding and staffing

IMMEDIATE FUNDING REQUIREMENT

Yes, please inquire